Hira Hameed

Hira Hameed

Auto-generated profile, based on publicly available information

Hira Hameed

Allama Iqbal Medical College, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Health Science Reports
Verified
Journal Article
Open access
MUMarha Zaheer Uddin
Marha Zaheer Uddin
HHHira Hameed
Hira Hameed
AIAnoosha Muhammad Iqbal
Anoosha Muhammad Iqbal
MIMuhamad Irfan
Muhamad Irfan
SMSanhia Maheshwari
Sanhia Maheshwari
Inibehe Ime OkonInibehe Ime Okon
Inibehe Ime Okon
Introduction: Osteoporosis is a bone disorder highly prevalent in post‐menopausal women and is an important predisposing factor towards bone fractures. It is commonly classified based on BMD, which is estimated via DEXA scan. It is an important issue worldwide and requires a multidisciplinary approach to be controlled. Methods: Utilizing online sources including PubMed, Embase, Cochrane, and Google Scholar, a thorough literature search was conducted. To determine the best treatment options with fewer difficulties and adverse events and more good results. There were discovered to be 15 RCTS that qualified. The study was carried out per PRISMA recommendations. Results: According to the outcomes generated from the study, there was a significantly reduced rate of overall vertebral and non‐vertebral fractures with teriparatide use along with data supporting increased BMD observed in the teriparatide group. Importantly, there was a reduction in death rate too observed in the intervention group. The results were also consistent with our various secondary outcomes. Conclusion: We can conclude from the outcomes that a clinically significant result was generated in the group using teriparatide in various aspects. There were still some confounding factors present that need to be addressed to increase the yield of the study, and with increasing research in the field, more comprehensive studies are required in the future to reach a definitive outcome.

26 February 2025 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
HHHira Hameed
Hira Hameed
SKSaad Khan
Saad Khan
SNSafa Nasir
Safa Nasir

28 February 2025 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AKAlina Zaman Khan
Alina Zaman Khan
SKSaad Khan
Saad Khan
HHHira Hameed
Hira Hameed
SNSafa Nasir
Safa Nasir
ZNZermeen Naveed
Zermeen Naveed

1 January 2026 in Pakistan Heart Journal
Verified
Journal Article
Open access
PDF file
FFFatima Faraz
Fatima Faraz
STShamaem Tariq
Shamaem Tariq
ISImran Saeed
Imran Saeed
HHHira Hameed
Hira Hameed
PTPakeezah Tabasum
Pakeezah Tabasum
MHMuhammad Usman Hashmi
Muhammad Usman Hashmi
This systematic review and meta-analysis evaluated the comparative efficacy of ezetimibe–statin combination therapy versus statin monotherapy in improving lipid profiles and cardiovascular outcomes in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). A comprehensive search across four databases yielded eight eligible studies comprising a total of 4,588 patients. Using a random-effects model, combination therapy was found to significantly reduce low-density lipoprotein cholesterol (LDL-C) (SMD −0.32; 95% CI: −0.50 to −0.15; P < 0.001) and total cholesterol (TC) (SMD −0.27; 95% CI: −0.53 to −0.01; P = 0.05) compared to statin monotherapy. No significant differences were observed in high-density lipoprotein cholesterol (HDL-C) (SMD 0.05; 95% CI: −0.13 to 0.23; P = 0.59), triglycerides (TG) (SMD 0.09; 95% CI: −0.27 to 0.08; P = 0.30), or major adverse cardiovascular events (MACE) (RR 1.61; 95% CI: 0.75 to 3.47; P = 0.22). These results suggest that ezetimibe in combination with statins is superior in lipid-lowering efficacy but does not translate into a statistically significant reduction in cardiovascular events. Further high-quality, large-scale randomized trials are warranted to assess the long-term cardiovascular benefits of combination therapy in this population.